Statement: Patients in the primary trial receive 5 doses of Azacitidine (Vidaza) every month and 3 doses of Nab-paclitaxel (Abraxane) per month.
Primary_evidence: INTERVENTION 1:    Phase 1   Azacitidine (Vidaza): 50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle   Nab-paclitaxel (Abraxane): 100mg/m2 weekly for 3 weeks of each 4-week cycle